| Similar Articles |
|---|
 |
The Motley Fool
January 23, 2009
Robert Steyer |
BAX to the Future After minding its own business, Baxter International starts thinking about acquisitions again.   |
The Motley Fool
October 16, 2009
Robert Steyer |
Baxter Beats Again -- the Streak Is Alive! The drug, device, and medical services giant beats Wall Street earnings estimates by a penny, but flat sales signal caution. |
The Motley Fool
February 24, 2009
Brian Orelli |
Pfizer: Diversified Dreams, Dubious Decisions Pfizer's CEO Jeffrey Kindler said he wants to make his company more like Johnson & Johnson and Abbott Labs, which aren't dependent on one product for success. |
The Motley Fool
July 20, 2007
Brian Orelli |
Baxter's Mixed Message A recall of Baxter BioScience's COLLEAGUE infusion pumps seems to have over-shadowed healthy quarterly earnings reports. |
Chemistry World
December 6, 2012
Andrew Turley |
Baxter to pay $4bn for dialysis firm US drug maker Baxter has struck a deal to buy privately-owned Swedish firm Gambro, which makes dialysis products, for $4 billion |
The Motley Fool
December 23, 2003
Jeff Hwang |
Bad, Bad Baxter The medical products company issues its latest in a series of earnings warnings. |
The Motley Fool
January 28, 2005
Brian Gorman |
Baxter Plods On 2005 looks like another year of transition for Baxter International. The medical products and services concern reported that after currency adjustments, fourth-quarter 2004 revenue of $2.6 billion was essentially flat compared with the same period in 2003. |
The Motley Fool
April 22, 2005
Brian Gorman |
Baxter Is on the Mend The medical products company continues to right itself for a brighter future. The firm's long-term positioning and diversified business may make it worth a closer look. |
The Motley Fool
November 3, 2011
Dan Caplinger |
Has Baxter International Become the Perfect Stock? Baxter needs to keep working on getting its debt levels down and seek out new growth opportunities. With favorable demographic winds at its back, Baxter could be the rare stock to actually reach perfection. |
The Motley Fool
April 20, 2006
Stephen D. Simpson |
Baxter Bags Better Margins This is a great business -- but only at the right price. Investors, this story has to be bought cheap. At today's prices, is it cheap enough? |
The Motley Fool
March 20, 2009
Brian Orelli |
No More Tears, Far More Fears? China's Food and Drug Administration said that it's investigating products made by our beloved Johnson & Johnson, after a U.S. group reported that there may be carcinogens in J&J's baby shampoo. |
The Motley Fool
April 18, 2008
Brian Orelli |
Recalls Can't Beat Baxter In spite of charges for two recalls, Baxter posts a decent quarter. |
Registered Rep.
June 14, 2007
Kevin Burke |
Pilgrim Baxter's Payback The SEC announced this week that it is returning ill-gotten gains to Pilgrim Baxter (investment advisor to the PBHG fund family) shareholders, three and half years after the fund company was engulfed in a trading scandal. |
Chemistry World
March 28, 2014
Phillip Broadwith |
Baxter aims to divide and conquer US drugmaker Baxter International is spinning off its biopharmaceuticals business to create two independent companies. |
The Motley Fool
July 17, 2008
Brian Orelli |
Investors Yawn at Abbott Labs' Growth Abbott Labs may be firing on all cylinders, but investors were less than impressed with its earnings release |
The Motley Fool
April 6, 2009 |
3 Stocks Hitting Low Notes These stocks have hit bottom. Are they ready to bounce? Take a look at: Baxter International... Abbott Laboratories... |
The Motley Fool
October 7, 2010
Anand Chokkavelu |
How Johnson & Johnson Really Makes Money Hint: It's not Tylenol. |
Registered Rep.
April 23, 2007
Kevin Burke |
At Last: Pilgrim Baxter Shareholders To Get `Market-Timing' Restitution The move is the first in a series of three disbursements from the Fair Fund coffers that will pay out $267 million to over 384,000 affected PBHG Funds shareholders. |
The Motley Fool
November 8, 2011
Brian Wilson |
2 Health-Care Stocks for Times of Uncertainty Just because Abbott and Johnson & Johnson don't undertake as much risk as other health-care giants doesn't mean that shareholders won't see impressive growth in revenues. |
The Motley Fool
February 29, 2008
Brian Orelli |
Bigger Recall, No Big Deal Baxter increases its recall of heparin, but investors shouldn't be that worried. |
The Motley Fool
October 19, 2007
Brian Orelli |
Baxter Gets Pumped Up Medical-device maker Baxter puts in a nice quarter despite two recent FDA recalls. |
HBS Working Knowledge
February 7, 2005
Mallory Stark |
How "Career Imprinting" Shapes Leaders Where you work early in your career shapes the kind of leader you become later on, says the author of the forthcoming book, Career Imprints: Creating Leaders Across an Industry. There is, for example, a GE imprint, an IBM imprint, a Bain imprint--all of which influence future decision makers. |
The Motley Fool
October 31, 2008
Brian Orelli |
From Precious to Precocious Natus Medical may make some acquisitions to continue boosting its revenue. |
The Motley Fool
June 30, 2009
Brian Orelli |
Johnson & Johnson Inflames Abbott $1.67 billion is one hefty reward. |
The Motley Fool
January 22, 2009
Brian Orelli |
Abbott Labs Thumbs Nose at Recession On a GAAP basis, Abbott Labs fourth-quarter earnings per share were up a whopping 27%, and even better, the double-digit increases don't look like they're going to stop anytime soon. |
Fast Company
April 2004
Keith H. Hammonds |
Moment of Truth? It has been a tortuous year for Harry M. Jansen Kraemer Jr., CEO of Baxter International Inc. Back in November 2002, we lauded Kraemer's forthright leadership as his company confronted the deaths of 53 patients due to contaminated dialysis filters made by a Baxter subsidiary. Now Kraemer is out of a job. |
The Motley Fool
April 24, 2007
Ryan Fuhrmann |
Earnings-eluting Time at Boston Scientific: Fool by Numbers The medical device firm released first-quarter 2007 results: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
The Motley Fool
October 20, 2005
Stephen D. Simpson |
Baxter Needs Growth Infusion This is a fine health-care company, but a sluggish top line suggests there are limits to how far it can go. Trading at nearly 20 times forward earnings, it seems like expectations of a growth revival are already in the stock. |
The Motley Fool
September 27, 2007
Billy Fisher |
Baxter Looking to Bounce Back Shares of the medical device maker finally rebound following a company recall of infusion pumps. |
The Motley Fool
September 24, 2008
Brian Orelli |
Hey, You! Stop! The FDA has ordered Baxter and Hospira to stop making their ophthalmic balanced salt solutions within 60 days. |
The Motley Fool
April 26, 2010
Jennifer Schonberger |
The S&P 500's Biggest Movers Meet the index's major players for the past week. |
The Motley Fool
April 10, 2008
Brian Orelli |
The News for Baxter Just Got Worse These heparin-related deaths aren't associated with Baxter's product, but they still might spell trouble for the company. |
The Motley Fool
July 13, 2009
Rick Aristotle Munarriz |
7 Reasons Not to Worry This Week Here are seven companies that are projected to grow their bottom lines this week. |
The Motley Fool
January 25, 2008
Brian Orelli |
Where the Big Margins Are Drug company investors get to enjoy such high gross margins, but there's generally only so much improvement that a company can make when it starts from such a high point. Take a look at some pharma companies that are succeeding to do just that. |
The Motley Fool
October 20, 2009
Brian Orelli |
Pfizer Starts the Blame Game Pfizer beat analysts' expectations for both revenue and adjusted earnings, but revenue was still lower than the year-ago quarter. Pfizer has excuses. |
Fast Company
November 2002
Keith H. Hammonds |
Harry Kraemer's Moment of Truth In an era when the business section read like the police blotter, the CEO of medical products and pharmaceutical company Baxter International faced a tough ethical dilemma. And he did something noteworthy: He actually did the right thing. |
The Motley Fool
October 12, 2009
Rick Aristotle Munarriz |
7 Reasons Not to Worry This Week Here are seven companies that analysts see posting healthier bottom lines this week: Google... IBM... Abbott Labs... Baxter International... JPMorgan Chase... Goldman Sachs... Citigroup... |
CIO
October 28, 2011
Kim S. Nash |
Why Legal Concerns Put a Halt to BYOT at Baxter Baxter International wanted to allow employees to bring their own devices to work, but legal concerns related to e-discovery had to be resolved first. |
